JP2018521691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521691A5 JP2018521691A5 JP2018522867A JP2018522867A JP2018521691A5 JP 2018521691 A5 JP2018521691 A5 JP 2018521691A5 JP 2018522867 A JP2018522867 A JP 2018522867A JP 2018522867 A JP2018522867 A JP 2018522867A JP 2018521691 A5 JP2018521691 A5 JP 2018521691A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- chain polypeptide
- protein
- tfr antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 238000010367 cloning Methods 0.000 claims 3
- 239000013599 cloning vector Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100001258 radiotoxin Toxicity 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192.4 | 2015-07-22 | ||
| EP15306192 | 2015-07-22 | ||
| PCT/EP2016/067465 WO2017013230A1 (en) | 2015-07-22 | 2016-07-21 | ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521691A JP2018521691A (ja) | 2018-08-09 |
| JP2018521691A5 true JP2018521691A5 (enExample) | 2019-08-29 |
| JP6858185B2 JP6858185B2 (ja) | 2021-04-14 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522867A Active JP6858185B2 (ja) | 2015-07-22 | 2016-07-21 | 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11230605B2 (enExample) |
| EP (1) | EP3325509B1 (enExample) |
| JP (1) | JP6858185B2 (enExample) |
| KR (1) | KR102690998B1 (enExample) |
| CN (1) | CN107849136B (enExample) |
| AU (1) | AU2016296321B2 (enExample) |
| CA (1) | CA2992509C (enExample) |
| CY (1) | CY1123941T1 (enExample) |
| DK (1) | DK3325509T3 (enExample) |
| ES (1) | ES2860988T3 (enExample) |
| HR (1) | HRP20210393T1 (enExample) |
| HU (1) | HUE053296T2 (enExample) |
| IL (1) | IL257065B (enExample) |
| LT (1) | LT3325509T (enExample) |
| MX (1) | MX2018000569A (enExample) |
| PL (1) | PL3325509T3 (enExample) |
| PT (1) | PT3325509T (enExample) |
| RS (1) | RS61586B1 (enExample) |
| RU (1) | RU2737637C2 (enExample) |
| SI (1) | SI3325509T1 (enExample) |
| SM (1) | SMT202100134T1 (enExample) |
| WO (1) | WO2017013230A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179817B2 (en) | 2015-05-04 | 2019-01-15 | Cytomx Therapeutics, Inc. | Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| CN112955153A (zh) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN112912499A (zh) | 2018-08-02 | 2021-06-04 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4069745A4 (en) * | 2019-11-06 | 2024-05-29 | The Regents Of The University Of California | Compositions and methods for transferrin receptor 1 targeting |
| IL295022A (en) * | 2020-01-31 | 2022-09-01 | Dyne Therapeutics Inc | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| MX2024002753A (es) | 2021-09-01 | 2024-05-20 | Biogen Ma Inc | Anticuerpos anti receptor de transferrina y usos de los mismos. |
| US20240376222A1 (en) * | 2021-09-13 | 2024-11-14 | The Board Of Regents Of The University Of Texas System | Tfr antigen binding proteins and uses thereof |
| CN119183457A (zh) | 2022-04-15 | 2024-12-24 | 达因疗法公司 | 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂 |
| EP4626923A1 (en) * | 2022-12-02 | 2025-10-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-tfr1 antibodies and uses thereof |
| TW202444759A (zh) | 2023-03-24 | 2024-11-16 | 美商戴納立製藥公司 | Ａβ靶向蛋白及使用方法 |
| EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
| WO2025090898A1 (en) * | 2023-10-26 | 2025-05-01 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof cross reference to related applications |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| HUP0104865A3 (en) * | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| ES2379526T3 (es) * | 2004-04-30 | 2012-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpo anti-TfR |
| KR101295139B1 (ko) * | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
| JP4361545B2 (ja) * | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| FR2953841B1 (fr) | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| US20150197574A1 (en) * | 2012-08-02 | 2015-07-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of transferrin receptor antagonist for the treatment of thalassemia |
| CN104797600A (zh) * | 2012-11-08 | 2015-07-22 | 国立大学法人宫崎大学 | 能够特异性识别转铁蛋白受体的抗体 |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 KR KR1020187004745A patent/KR102690998B1/ko active Active
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en not_active Ceased
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
- 2016-07-21 CA CA2992509A patent/CA2992509C/en active Active
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 SM SM20210134T patent/SMT202100134T1/it unknown
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
-
2021
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US12037408B2/en active Active